Dr. Murphy has lost colleagues to diseases that are linked to long-term occupational radiation exposure and, as a practicing physician himself, long recognized the need for better ways to counter radiation exposure. In 2011 he began developing an antioxidant formulation to help prevent cellular and mitochondrial damage from oxidative stress. The end result is Halo, the first product launched by Cora Therapeutics.
Research and data are at the core of our company ethos. Our formulations are developed using the wealth of knowledge possessed by our team and validated through clinical research.
Halo Antioxidant is our first product, available now in Canada, and launching fall 2023 in the United States.